By Editor • September 14, 2026 • 1 min read
Novo Nordisk rebrands as 'Novo' in a bid to regain market momentum following a decline in stock and competition challenges.
Read moreBy Editor • September 13, 2026 • 1 min read
An analysis indicates that the Trump administration's drug pricing strategy may face an 80% reduction in projected savings due to undisclosed pharmaceutical deals.
Read moreBy Editor • September 11, 2026 • 1 min read
A European Union Advocate General recommends annulling part of a directive that burdens the pharmaceutical industry with wastewater treatment costs.
Read moreBy Editor • September 9, 2026 • 1 min read
A Citi survey shows only 24% of US pharma executives believe AI will lead to successful drug development, despite its widespread adoption in research.
Read moreBy Editor • September 3, 2026 • 1 min read
Abivax, a promising French biotech firm, remains unacquired despite expectations of a $20 billion deal, leaving investors concerned.
Read moreBy Editor • September 2, 2026 • 1 min read
Trump's new drug pricing deals with biotech firms may not effectively reduce costs, primarily impacting Medicaid but exempting Medicare.
Read moreBy Editor • September 1, 2026 • 1 min read
The Trump administration's announcement of drug pricing deals raises significant unanswered questions about their implications.
Read moreBy Editor • August 31, 2026 • 1 min read
Trump announces new deals with nine drugmakers to ensure lower prices for U.S. patients and Medicaid programs.
Read moreBy Editor • August 14, 2026 • 1 min read
Formation Bio has appointed Michael Ehlers as chief scientific officer, previously CEO of Ascidian Therapeutics.
Read more
